STOCK TITAN

[8-K] Anavex Life Sciences Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.

The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.

Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.

The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.

Il Schedule 13G depositato il 3 luglio 2025 rivela che Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC possiedono collettivamente 153.219 azioni ordinarie di Bone Biologics Corporation (BBLG), pari al 9,99% della classe. La posizione comprende 148.500 azioni emesse e 4.791 azioni sottostanti al Warrant 2 di Intracoastal; il potere di voto e di disposizione è condiviso tra i tre soggetti segnalanti.

La partecipazione deriva da un Accordo di Acquisto di Titoli firmato il 27 giugno 2025, in base al quale la Società ha emesso 60.000 azioni e sette warrant separati a favore di Intracoastal. Ogni warrant include una clausola “blocco” che impedisce l’esercizio qualora la proprietà effettiva del gruppo superi il 9,99% (o il 4,99% per alcuni warrant minori). Grazie a queste clausole, il gruppo rimane al di sotto della soglia del 10% richiesta per la segnalazione ai sensi della Sezione 16.

Senza tali clausole di blocco, il gruppo segnalante potrebbe controllare fino a 821.294 azioni immediatamente dopo l’Accordo e 719.794 azioni al 3 luglio 2025—più di 1,3 volte le 545.260 azioni in circolazione al 20 giugno 2025—indicando un potenziale significativo diluizione per gli azionisti esistenti nel caso in cui i warrant diventino esercitabili.

La sezione di certificazione afferma che i titoli non sono stati acquisiti per influenzare il controllo dell’emittente. Tuttavia, gli investitori dovrebbero monitorare (1) il ritmo di esercizio dei warrant, (2) eventuali modifiche alle soglie di blocco e (3) futuri aggiornamenti del Schedule 13D/G che potrebbero indicare un cambiamento di intento o di proprietà.

El Schedule 13G presentado el 3 de julio de 2025 revela que Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC poseen colectivamente 153,219 acciones ordinarias de Bone Biologics Corporation (BBLG), equivalentes al 9,99% de la clase. La posición consiste en 148,500 acciones emitidas y 4,791 acciones subyacentes al Warrant 2 de Intracoastal; todo el poder de voto y disposición se comparte entre las tres personas que reportan.

La participación proviene de un Acuerdo de Compra de Valores firmado el 27 de junio de 2025, bajo el cual la Compañía emitió 60,000 acciones y siete warrants separados a Intracoastal. Cada warrant contiene un “bloqueador” de propiedad que impide su ejercicio si la propiedad beneficiaria del grupo excede el 9,99% (o el 4,99% para varios warrants menores). Debido a estos bloqueadores, el grupo permanece por debajo del umbral del 10% requerido para el reporte bajo la Sección 16.

Sin las disposiciones de bloqueo, el grupo reportante podría controlar hasta 821,294 acciones inmediatamente después del SPA y 719,794 acciones al 3 de julio de 2025—más de 1.3 veces las 545,260 acciones en circulación al 20 de junio de 2025—lo que indica una dilución potencial significativa para los tenedores actuales si los warrants se vuelven ejercitables.

La sección de certificación indica que los valores no fueron adquiridos para influir en el control del emisor. No obstante, los inversores deberían monitorear (1) el ritmo de ejercicio de los warrants, (2) cualquier enmienda a los límites de bloqueo y (3) futuras actualizaciones del Schedule 13D/G que podrían señalar un cambio en la intención o propiedad.

2025년 7월 3일 제출된 Schedule 13G에 따르면 Mitchell P. Kopin, Daniel B. Asher 및 Intracoastal Capital LLC가 공동으로 Bone Biologics Corporation(BBLG) 보통주 153,219주를 보유하고 있으며, 이는 전체 클래스의 9.99%에 해당합니다. 이 지분은 148,500주의 발행주식과 Intracoastal 워런트 2에 기초한 4,791주로 구성되며, 모든 의결권 및 처분권은 세 명의 보고자 간에 공유됩니다.

이 지분은 2025년 6월 27일 체결된 증권 매매계약(Securities Purchase Agreement)에서 비롯되었으며, 이에 따라 회사는 Intracoastal에 60,000주와 7개의 개별 워런트를 발행했습니다. 각 워런트에는 그룹의 실질 소유가 9.99%를 초과할 경우(일부 소규모 워런트는 4.99%) 행사를 제한하는 '블로커' 조항이 포함되어 있습니다. 이러한 블로커 조항 덕분에 그룹은 섹션 16 보고에 필요한 10% 임계값을 넘지 않고 있습니다.

블로커 조항이 없었다면, 보고 그룹은 SPA 직후 최대 821,294주를, 2025년 7월 3일 기준으로는 719,794주를 보유할 수 있었으며, 이는 2025년 6월 20일 기준 발행주식 545,260주의 1.3배 이상에 해당하여, 워런트가 행사 가능해질 경우 기존 주주들에게 상당한 희석 가능성을 시사합니다.

인증 섹션에서는 해당 증권이 발행사의 지배권에 영향을 미치기 위해 취득되지 않았다고 명시되어 있습니다. 그럼에도 불구하고 투자자들은 (1) 워런트 행사 속도, (2) 블로커 임계값 변경 사항, (3) 의도나 소유권 변화를 알릴 수 있는 향후 Schedule 13D/G 업데이트를 주시해야 합니다.

Le Schedule 13G déposé le 3 juillet 2025 révèle que Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC détiennent collectivement 153 219 actions ordinaires de Bone Biologics Corporation (BBLG), soit 9,99 % de la catégorie. La position comprend 148 500 actions émises et 4 791 actions sous-jacentes au Warrant 2 d’Intracoastal ; tous les pouvoirs de vote et de disposition sont partagés entre les trois personnes déclarantes.

Cette participation provient d’un Accord d’Achat de Titres signé le 27 juin 2025, en vertu duquel la Société a émis 60 000 actions et sept warrants distincts à Intracoastal. Chaque warrant comporte un « bloqueur » de propriété empêchant l’exercice si la propriété bénéficiaire du groupe dépasse 9,99 % (ou 4,99 % pour plusieurs warrants plus petits). Grâce à ces bloqueurs, le groupe reste en dessous du seuil de 10 % requis pour la déclaration en vertu de la Section 16.

Sans ces clauses de blocage, le groupe déclarant pourrait contrôler jusqu’à 821 294 actions immédiatement après l’Accord et 719 794 actions au 3 juillet 2025 — soit plus de 1,3 fois les 545 260 actions en circulation au 20 juin 2025 — indiquant une dilution potentielle importante pour les détenteurs actuels si les warrants deviennent exerçables.

La section de certification indique que les titres n’ont pas été acquis dans le but d’influencer le contrôle de l’émetteur. Néanmoins, les investisseurs devraient surveiller (1) le rythme d’exercice des warrants, (2) toute modification des seuils de blocage, et (3) les futures mises à jour du Schedule 13D/G qui pourraient signaler un changement d’intention ou de propriété.

Das am 3. Juli 2025 eingereichte Schedule 13G zeigt, dass Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC gemeinsam 153.219 Stammaktien der Bone Biologics Corporation (BBLG) besitzen, was 9,99 % der Klasse entspricht. Die Position besteht aus 148.500 ausgegebenen Aktien und 4.791 Aktien, die dem Intracoastal Warrant 2 zugrunde liegen; alle Stimm- und Verfügungsrechte werden zwischen den drei meldenden Personen geteilt.

Der Anteil stammt aus einem Wertpapierkaufvertrag (Securities Purchase Agreement) vom 27. Juni 2025, unter dem das Unternehmen 60.000 Aktien und sieben separate Warrants an Intracoastal ausgegeben hat. Jeder Warrant enthält eine Besitz-“Blocker”-Klausel, die die Ausübung verhindert, wenn der wirtschaftliche Eigentumsanteil der Gruppe 9,99 % (bzw. 4,99 % bei mehreren kleineren Warrants) überschreiten würde. Aufgrund dieser Blocker bleibt die Gruppe unter der 10 %-Schwelle, die für die Meldung nach Abschnitt 16 erforderlich ist.

Ohne die Blocker-Bestimmungen könnte die meldende Gruppe unmittelbar nach dem SPA bis zu 821.294 Aktien und zum 3. Juli 2025 719.794 Aktien kontrollieren – mehr als das 1,3-fache der am 20. Juni 2025 ausstehenden 545.260 Aktien – was auf eine erhebliche potenzielle Verwässerung für bestehende Inhaber hinweist, falls die Warrants ausgeübt werden.

Der Zertifizierungsabschnitt besagt, dass die Wertpapiere nicht erworben wurden, um die Kontrolle über den Emittenten zu beeinflussen. Dennoch sollten Investoren (1) das Tempo der Warrantausübungen, (2) Änderungen der Blocker-Schwellenwerte und (3) zukünftige Updates des Schedule 13D/G beobachten, die auf eine Änderung der Absicht oder des Eigentums hinweisen könnten.

Positive
  • Capital commitment: Intracoastal received shares and warrants through a Securities Purchase Agreement, supplying fresh equity capital to Bone Biologics.
  • Ownership blockers cap the reporting group’s stake at 9.99 %, limiting immediate dilution and preventing a sudden change-of-control situation.
Negative
  • Warrant overhang: Up to ~720k–820k additional shares could be issued, potentially more than doubling the current float and diluting existing shareholders.
  • Concentrated voting power: All 153,219 shares are subject to shared voting/dispositive control, enabling coordinated action if intent changes.

Insights

TL;DR: 9.99 % cap keeps current dilution modest, but warrants could more than double float if blockers waived.

The filing confirms a near-control threshold stake by Intracoastal and its principals, obtained via a recent capital raise. Present ownership is below 10 %, limiting immediate governance impact. However, the warrants—many struck with identical 9.99 % or 4.99 % blockers—could expand the share count by roughly 720k–820k shares relative to a 545k base, a dilution risk exceeding 100 %. The investors’ certification of passive intent and the presence of blockers mitigate near-term concerns, yet the large option overhang warrants close monitoring. From a valuation perspective, the market should factor in potential supply as the company’s share count is already small.

TL;DR: Coordinated 9.99 % holding signals passive status now, but sizable warrants confer future influence potential.

The group’s Schedule 13G (rather than 13D) filing and explicit certification indicate no present activism agenda. Shared voting and dispositive power among Kopin, Asher and Intracoastal suggests unified action if their stance changes. Blocker provisions strategically keep the group just under governance trigger points while preserving economic upside. Should corporate events lift the blockers—through share-count expansion or waiver—the investors could rapidly shift to an active stance with >10 % ownership. Current impact is therefore neutral, but governance risk rises if cumulative exercises breach thresholds.

Il Schedule 13G depositato il 3 luglio 2025 rivela che Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC possiedono collettivamente 153.219 azioni ordinarie di Bone Biologics Corporation (BBLG), pari al 9,99% della classe. La posizione comprende 148.500 azioni emesse e 4.791 azioni sottostanti al Warrant 2 di Intracoastal; il potere di voto e di disposizione è condiviso tra i tre soggetti segnalanti.

La partecipazione deriva da un Accordo di Acquisto di Titoli firmato il 27 giugno 2025, in base al quale la Società ha emesso 60.000 azioni e sette warrant separati a favore di Intracoastal. Ogni warrant include una clausola “blocco” che impedisce l’esercizio qualora la proprietà effettiva del gruppo superi il 9,99% (o il 4,99% per alcuni warrant minori). Grazie a queste clausole, il gruppo rimane al di sotto della soglia del 10% richiesta per la segnalazione ai sensi della Sezione 16.

Senza tali clausole di blocco, il gruppo segnalante potrebbe controllare fino a 821.294 azioni immediatamente dopo l’Accordo e 719.794 azioni al 3 luglio 2025—più di 1,3 volte le 545.260 azioni in circolazione al 20 giugno 2025—indicando un potenziale significativo diluizione per gli azionisti esistenti nel caso in cui i warrant diventino esercitabili.

La sezione di certificazione afferma che i titoli non sono stati acquisiti per influenzare il controllo dell’emittente. Tuttavia, gli investitori dovrebbero monitorare (1) il ritmo di esercizio dei warrant, (2) eventuali modifiche alle soglie di blocco e (3) futuri aggiornamenti del Schedule 13D/G che potrebbero indicare un cambiamento di intento o di proprietà.

El Schedule 13G presentado el 3 de julio de 2025 revela que Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC poseen colectivamente 153,219 acciones ordinarias de Bone Biologics Corporation (BBLG), equivalentes al 9,99% de la clase. La posición consiste en 148,500 acciones emitidas y 4,791 acciones subyacentes al Warrant 2 de Intracoastal; todo el poder de voto y disposición se comparte entre las tres personas que reportan.

La participación proviene de un Acuerdo de Compra de Valores firmado el 27 de junio de 2025, bajo el cual la Compañía emitió 60,000 acciones y siete warrants separados a Intracoastal. Cada warrant contiene un “bloqueador” de propiedad que impide su ejercicio si la propiedad beneficiaria del grupo excede el 9,99% (o el 4,99% para varios warrants menores). Debido a estos bloqueadores, el grupo permanece por debajo del umbral del 10% requerido para el reporte bajo la Sección 16.

Sin las disposiciones de bloqueo, el grupo reportante podría controlar hasta 821,294 acciones inmediatamente después del SPA y 719,794 acciones al 3 de julio de 2025—más de 1.3 veces las 545,260 acciones en circulación al 20 de junio de 2025—lo que indica una dilución potencial significativa para los tenedores actuales si los warrants se vuelven ejercitables.

La sección de certificación indica que los valores no fueron adquiridos para influir en el control del emisor. No obstante, los inversores deberían monitorear (1) el ritmo de ejercicio de los warrants, (2) cualquier enmienda a los límites de bloqueo y (3) futuras actualizaciones del Schedule 13D/G que podrían señalar un cambio en la intención o propiedad.

2025년 7월 3일 제출된 Schedule 13G에 따르면 Mitchell P. Kopin, Daniel B. Asher 및 Intracoastal Capital LLC가 공동으로 Bone Biologics Corporation(BBLG) 보통주 153,219주를 보유하고 있으며, 이는 전체 클래스의 9.99%에 해당합니다. 이 지분은 148,500주의 발행주식과 Intracoastal 워런트 2에 기초한 4,791주로 구성되며, 모든 의결권 및 처분권은 세 명의 보고자 간에 공유됩니다.

이 지분은 2025년 6월 27일 체결된 증권 매매계약(Securities Purchase Agreement)에서 비롯되었으며, 이에 따라 회사는 Intracoastal에 60,000주와 7개의 개별 워런트를 발행했습니다. 각 워런트에는 그룹의 실질 소유가 9.99%를 초과할 경우(일부 소규모 워런트는 4.99%) 행사를 제한하는 '블로커' 조항이 포함되어 있습니다. 이러한 블로커 조항 덕분에 그룹은 섹션 16 보고에 필요한 10% 임계값을 넘지 않고 있습니다.

블로커 조항이 없었다면, 보고 그룹은 SPA 직후 최대 821,294주를, 2025년 7월 3일 기준으로는 719,794주를 보유할 수 있었으며, 이는 2025년 6월 20일 기준 발행주식 545,260주의 1.3배 이상에 해당하여, 워런트가 행사 가능해질 경우 기존 주주들에게 상당한 희석 가능성을 시사합니다.

인증 섹션에서는 해당 증권이 발행사의 지배권에 영향을 미치기 위해 취득되지 않았다고 명시되어 있습니다. 그럼에도 불구하고 투자자들은 (1) 워런트 행사 속도, (2) 블로커 임계값 변경 사항, (3) 의도나 소유권 변화를 알릴 수 있는 향후 Schedule 13D/G 업데이트를 주시해야 합니다.

Le Schedule 13G déposé le 3 juillet 2025 révèle que Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC détiennent collectivement 153 219 actions ordinaires de Bone Biologics Corporation (BBLG), soit 9,99 % de la catégorie. La position comprend 148 500 actions émises et 4 791 actions sous-jacentes au Warrant 2 d’Intracoastal ; tous les pouvoirs de vote et de disposition sont partagés entre les trois personnes déclarantes.

Cette participation provient d’un Accord d’Achat de Titres signé le 27 juin 2025, en vertu duquel la Société a émis 60 000 actions et sept warrants distincts à Intracoastal. Chaque warrant comporte un « bloqueur » de propriété empêchant l’exercice si la propriété bénéficiaire du groupe dépasse 9,99 % (ou 4,99 % pour plusieurs warrants plus petits). Grâce à ces bloqueurs, le groupe reste en dessous du seuil de 10 % requis pour la déclaration en vertu de la Section 16.

Sans ces clauses de blocage, le groupe déclarant pourrait contrôler jusqu’à 821 294 actions immédiatement après l’Accord et 719 794 actions au 3 juillet 2025 — soit plus de 1,3 fois les 545 260 actions en circulation au 20 juin 2025 — indiquant une dilution potentielle importante pour les détenteurs actuels si les warrants deviennent exerçables.

La section de certification indique que les titres n’ont pas été acquis dans le but d’influencer le contrôle de l’émetteur. Néanmoins, les investisseurs devraient surveiller (1) le rythme d’exercice des warrants, (2) toute modification des seuils de blocage, et (3) les futures mises à jour du Schedule 13D/G qui pourraient signaler un changement d’intention ou de propriété.

Das am 3. Juli 2025 eingereichte Schedule 13G zeigt, dass Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC gemeinsam 153.219 Stammaktien der Bone Biologics Corporation (BBLG) besitzen, was 9,99 % der Klasse entspricht. Die Position besteht aus 148.500 ausgegebenen Aktien und 4.791 Aktien, die dem Intracoastal Warrant 2 zugrunde liegen; alle Stimm- und Verfügungsrechte werden zwischen den drei meldenden Personen geteilt.

Der Anteil stammt aus einem Wertpapierkaufvertrag (Securities Purchase Agreement) vom 27. Juni 2025, unter dem das Unternehmen 60.000 Aktien und sieben separate Warrants an Intracoastal ausgegeben hat. Jeder Warrant enthält eine Besitz-“Blocker”-Klausel, die die Ausübung verhindert, wenn der wirtschaftliche Eigentumsanteil der Gruppe 9,99 % (bzw. 4,99 % bei mehreren kleineren Warrants) überschreiten würde. Aufgrund dieser Blocker bleibt die Gruppe unter der 10 %-Schwelle, die für die Meldung nach Abschnitt 16 erforderlich ist.

Ohne die Blocker-Bestimmungen könnte die meldende Gruppe unmittelbar nach dem SPA bis zu 821.294 Aktien und zum 3. Juli 2025 719.794 Aktien kontrollieren – mehr als das 1,3-fache der am 20. Juni 2025 ausstehenden 545.260 Aktien – was auf eine erhebliche potenzielle Verwässerung für bestehende Inhaber hinweist, falls die Warrants ausgeübt werden.

Der Zertifizierungsabschnitt besagt, dass die Wertpapiere nicht erworben wurden, um die Kontrolle über den Emittenten zu beeinflussen. Dennoch sollten Investoren (1) das Tempo der Warrantausübungen, (2) Änderungen der Blocker-Schwellenwerte und (3) zukünftige Updates des Schedule 13D/G beobachten, die auf eine Änderung der Absicht oder des Eigentums hinweisen könnten.

false 0001314052 0001314052 2025-07-03 2025-07-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 3, 2025

 

ANAVEX LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada 001-37606 98-0608404
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

630 5th Avenue

20th Floor

New York, NY 10111

(Address of principal executive offices) (Zip Code)

 

1-844-689-3939

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share   AVXL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 3, 2025 and effective July 5, 2025, Anavex Life Sciences Corp., a Nevada corporation (the “Company”), entered into the Fourth Amendment to Employment Agreement (the “Missling Amendment”) with Christopher Missling, PhD, in his continuing capacity as Chief Executive Officer of the Company. The Missling Amendment amends the Employment Agreement by and between the Company and Dr. Missling, dated June 27, 2013, as most recently amended by the Third Amendment to Employment Agreement dated April 7, 2022 (as amended, the “Missling Employment Agreement”).

 

The Missling Amendment is made to extend the term of the Missling Employment Agreement through July 5, 2028, unless earlier terminated as provided in the Missling Amendment. Pursuant to the terms of the Missling Amendment, beginning July 5, 2025, Dr. Missling shall receive an annual base salary of $800,000 and is eligible to earn an annual cash target bonus for each whole or partial calendar year of twenty percent of his base salary and an annual equity grant in an amount to be determined by the compensation committee of the Company’s board of directors.

 

Additionally, effective July 3, 2025, the Company entered into the Third Amendment to Employment Agreement (the “Boenisch Amendment”) with Sandra Boenisch, in her continuing capacity as Principal Financial Officer of the Company. The Boenisch Amendment amends the Amended and Restated Employment Agreement by and between the Company and the PFO dated October 4, 2017, as most recently amended by the Second Amendment to Employment Agreement dated February 28, 2022 (as amended, the “Boenisch Employment Agreement”).

 

The Boenisch Amendment provides that the term of the Boenisch Employment Agreement shall continue indefinitely, unless terminated as provided in the Boenisch Amendment. Pursuant to the terms of the Boenisch Amendment, Ms. Boenisch shall receive an annual base salary of $279,840 Canadian Dollars and is eligible to earn an annual cash target bonus for each calendar year of twenty percent of her base salary. The Boenisch Amendment also amended the termination provisions of the Boenisch Employment Agreement, including to increase the amount of severance owed to Ms. Boenisch if she is terminated without cause from six (6) months to twelve (12) months of her base salary, and provides for additional employment related benefits for Ms. Boenisch.

 

The summary of the Missling Amendment and the Boenisch Amendment provided herein is qualified in their entirety by the terms of such agreement, which are fully set forth and attached hereto as Exhibits 10.1 and 10.2, respectively, and which are incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

EXHIBIT NO.     DESCRIPTION   LOCATION
10.1     Fourth Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Christopher Missling, PhD, dated July 3, 2025   Filed herewith
10.2     Third Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Sandra Boenisch, dated July 3, 2025   Filed herewith
104     Cover Page Interactive Data File (embedded within the Inline XBRL document)    

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANAVEX LIFE SCIENCES CORP.
   
  By: /s/ Christopher Missling
    Name: Christopher Missling, PhD
Title: Chief Executive Officer

 

Date: July 3, 2025

 

 

FAQ

How much of Bone Biologics (BBLG) do Intracoastal and its principals currently own?

They beneficially own 153,219 shares, or 9.99 % of the outstanding common stock.

What is the maximum number of BBLG shares that could be issued under the warrants held by Intracoastal?

If all blocker provisions were removed, the group could control up to 719,794–821,294 shares depending on the reference date.

Why do the warrants include 9.99 % and 4.99 % blocker provisions?

The blockers prevent warrant exercise that would raise beneficial ownership above specified thresholds, avoiding Section 16 obligations and potential change-of-control triggers.

When was the Securities Purchase Agreement executed?

The SPA was signed on 27 June 2025, with the closing referenced in the filing.

How many shares outstanding were used to calculate the 9.99 % ownership?

The filing references 545,260 shares outstanding as of 20 June 2025.

Do the reporting persons intend to influence control of Bone Biologics?

Their certification states the securities were not acquired for the purpose of changing or influencing control.
Anavex Life Scie

NASDAQ:AVXL

AVXL Rankings

AVXL Latest News

AVXL Stock Data

921.16M
82.53M
3.04%
35.16%
27.56%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK